With the software solutions Ariol and SlidePath, Leica Microsystems now adds the ability to store, manage, analyze, and report on digital images created with the Leica SCN400 Slide Scanner or the Leica DM6000 B Research Microscope.
ForteBio, Inc., a supplier of label-free technology, announced the launch of its Dip and Read Protein G biosensor for rapid detection and quantification of numerous types of mammalian immunoglobulin, from solution.
Zyleris PharmaTech has announced the launch of its high-throughput formulation screening service for topical and transdermal drug development based on the company’s innovative experimentation technology.
Protea Biosciences announced that the company has concluded an exclusive, worldwide license agreement with George Washington University for commercial rights to a new technology that provides rapid identification of a broad range of chemicals and biomolecules.
One such obstacle frustrating stem cell researchers is "cell death" that the major types of hPS cells, including human embryonic stem cells and human induced pluripotent stem cells, mysteriously undergo when cultured as single cells, rendering them less suitable for research.
Using high-resolution microscopy, researchers at the National Institutes of Health have shown how insulin prompts fat cells to take in glucose in a rat model.
Cumberland Pharmaceuticals Inc. announced the publication of new data supporting the safety and efficacy of Caldolor (ibuprofen) Injection in pre- and post-operative orthopedic surgery patients.
DARA BioSciences announced that it presented study results from its Phase 2 multicenter, placebo controlled, double-blind, randomized dose escalation study for KRN5500 at the 13th World Congress on Pain held recently in Montreal.
To help advance research on how genes affect responses to medicines, the National Institutes of Health is spending $15 million over five years to expand a key resource, the Pharmacogenomics Knowledge Base (PharmGKB).
Merck & Co. said its schizophrenia drug Saphris has been approved for two additional uses by the Food and Drug Administration.
If you thought passing the health care overhaul was messy, wait until Republicans try to repeal it if they regain power this fall. It could come down to who blinks first, with some Republicans raising the prospect of a government shutdown.
Onyx Pharmaceuticals Inc. said it could receive more than $300 million through an agreement with Ono Pharmaceutical Co. Ltd. to develop and sell two potential cancer treatments in Japan.
Drugmaker Merck & Co. said that arbitration will begin in late September in its dispute with Johnson & Johnson over revenue from two blockbuster drugs for rheumatoid arthritis and other immune disorders.
Bristol-Myers Squibb Co. said it will acquire biotechnology partner ZymoGenetics Inc. for $885 million in another move by a major drugmaker to boost its pipeline by snapping up a smaller developer.
Abbott has completed its acquisition of Piramal's Healthcare Solutions business, propelling it to market leadership in the Indian pharmaceutical market and further accelerating the company's growth in emerging markets.